Cargando…

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.

In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged less than 60 years with poor-prognosis, high-grad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, S. M., Radford, J. A., Dobson, L., Huq, T., Ryder, W. D., Pettengell, R., Morgenstern, G. R., Scarffe, J. H., Crowther, D.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150159/ https://www.ncbi.nlm.nih.gov/pubmed/9579836

Ejemplares similares

Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma
por: Clamp, A R, et al.
Publicado: (2008)

Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer.
por: Steward, W. P., et al.
Publicado: (1990)

Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
por: Advani, S. H., et al.
Publicado: (2010)

In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients.
por: Bronchud, M. H., et al.
Publicado: (1988)

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.
por: Weaver, A., et al.
Publicado: (1996)

Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.
por: Steward, W. P., et al.
Publicado: (1989)

Phase I study of mitozantrone, methotrexate and mitomycin with granulocyte colony-stimulating factor (filgrastim) in patients with advanced breast cancer.
por: O'Brien, M. E., et al.
Publicado: (1994)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer.
por: Bronchud, M. H., et al.
Publicado: (1987)

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups
por: Pettengell, Ruth, et al.
Publicado: (2011)

Stimulating More Than Just the Granulocytes: Drug-Induced Liver Injury From Filgrastim
por: Sharma, Disha, et al.
Publicado: (2019)

Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donors
por: Berger, C, et al.
Publicado: (1999)

Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim) – a prospective, placebo-controlled, double-blind study
por: Kaukonen, Kirsi-Maija, et al.
Publicado: (2013)

Colchicine ultrasensitivity of peripheral-blood lymphocytes from patients with non-Hodgkin's lymphoma.
por: Scarffe, J. H., et al.
Publicado: (1980)

Filgrastim (r-metHuG-CSF) in clinical practice. Basic and clinical oncology series/5
por: Crowther, D.
Publicado: (1994)

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan
por: Yoshimura, Hideaki, et al.
Publicado: (2017)

High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.
por: Kanfer, E. J., et al.
Publicado: (1998)

Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.
por: Yokose, N., et al.
Publicado: (1998)

Male fertility after VAPEC-B chemotherapy for Hodgkin's disease and non-Hodgkin's lymphoma.
por: Radford, J. A., et al.
Publicado: (1994)

Prognostic factors in high and intermediate grade non-Hodgkin's lymphoma.
por: Cowan, R. A., et al.
Publicado: (1989)

Hodgkin's Disease
por: Scarffe, J. H.
Publicado: (1976)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue.
por: Dunlop, D. J., et al.
Publicado: (1994)

Filgrastim, fibrinolysis, and neovascularization
por: Eton, Darwin, et al.
Publicado: (2022)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021)

Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies
por: Ria, Roberto, et al.
Publicado: (2014)

Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)
por: Naeim, Arash, et al.
Publicado: (2013)

A Rare Case of Severe Neutropenia Due to Chikungunya Fever Which Improved With Filgrastim
por: Huq, Muhammad Rezeul, et al.
Publicado: (2021)

Risk factors for neutropenic fever in non- Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis
por: Kim, Yu Ri, et al.
Publicado: (2021)

Granulocyte Colony-Stimulating Factor Promotes Atherosclerosis in High-Fat Diet Rabbits
por: Hu, Zhaohui, et al.
Publicado: (2013)

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.
por: Bronchud, M. H., et al.
Publicado: (1989)

High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase II study.
por: Pronzato, P., et al.
Publicado: (1998)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Highly Expressed Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte Colony-Stimulating Factor Receptor (G-CSFR) in Human Gastric Cancer Leads to Poor Survival
por: Fan, Zhisong, et al.
Publicado: (2018)

Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.
por: Pedrazzoli, P., et al.
Publicado: (1997)

Granulocyte colony-stimulating factor and leukemogenesis.
por: de Figueiredo, Lorena Lobo, et al.
Publicado: (2004)

Prognostic factors for disease progression in advanced Hodgkin's disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy.
por: Lee, S. M., et al.
Publicado: (1997)

The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function.
por: Radford, J. A., et al.
Publicado: (1990)

Interleukin‐6 and Granulocyte Colony‐stimulating Factor Synergistically Increase Peripheral Blood Progenitor Cells in Myelosuppressive Mice
por: Suzuki, Hideki, et al.
Publicado: (1996)

Granulocyte Colony-Stimulating Factor Improves Endothelial Progenitor Cell-Mediated Neovascularization in Mice with Chronic Kidney Disease
por: Tang, Shao-Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h57k87h4s16ie8r1p82bgvd2ba